Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2006-02-03
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 493
- Registration Number
- NCT00286494
Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia.
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1267
- Registration Number
- NCT00268697
Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia
Phase 3
Terminated
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: Current lipid-lowering treatment
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 44
- Registration Number
- NCT00263081
Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506)
Phase 4
Completed
- Conditions
- Gastroesophageal RefluxGERDGORD
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 300
- Registration Number
- NCT00261339
- Locations
- 🇬🇧
Altana Pharma/Nycomed, Watford, United Kingdom
Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)
Phase 3
Completed
- Conditions
- Gastroesophageal Reflux Disease (GERD)Peptic Ulcers
- Interventions
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 100
- Registration Number
- NCT00261300
- Locations
- 🇩🇪
Altana Pharma/Nycomed, Hannover, Germany
Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 411
- Registration Number
- NCT00256178
Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis
Phase 3
Completed
- Conditions
- Esophagitis, RefluxEsophagitis, Peptic
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 451
- Registration Number
- NCT00255164
Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis
Phase 3
Completed
- Conditions
- Esophagitis, RefluxEsophagitis, Peptic
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 451
- Registration Number
- NCT00255151
Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2016-07-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 591
- Registration Number
- NCT00255190
Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn
Phase 3
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2010-05-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 908
- Registration Number
- NCT00251758
© Copyright 2025. All Rights Reserved by MedPath